Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-12-30 Ikarian Capital, LLC Member of 10% Group Buy 520,291 $9.61 $4,999,997 No
2020-12-29 WIGGINS MARK C Chief Business Officer Buy 1,000 $10.57 $10,570 No
2020-12-22 Opaleye Management Inc. 10%-Owner Buy 496,277 $8.06 $3,999,993 No
2020-11-11 Ikarian Capital, LLC Member of 10% Group Buy 34,000 $5.10 $173,269 No
2020-10-21 Opaleye Management Inc. 10%-Owner Buy 8,656 $4.40 $38,060 No
2020-10-21 THEUER CHARLES President and CEO Buy 2,000 $4.38 $8,769 No
2020-09-24 Opaleye Management Inc. 10%-Owner Buy 78,734 $4.73 $372,095 No
2020-09-23 THEUER CHARLES President and CEO Buy 5,000 $4.72 $23,599 No
2020-09-11 Ikarian Capital, LLC Member of 10% Group Buy 322,471 $3.28 $1,057,387 No
2020-09-11 Ikarian Capital, LLC Member of 10% Group Buy 322,471 $3.28 $1,057,387 No
2020-09-10 WIGGINS MARK C Chief Business Officer Buy 7,000 $4.14 $28,953 No
2020-09-09 Opaleye Management Inc. 10%-Owner Buy 56,558 $3.38 $190,902 No
2020-09-04 THEUER CHARLES President and CEO Buy 10,000 $2.58 $25,750 No
2020-09-02 Opaleye Management Inc. 10%-Owner Buy 159,800 $2.28 $363,825 No
2020-08-31 Opaleye Management Inc. 10%-Owner Buy 545,504 $1.74 $950,378 Yes
2020-08-21 THEUER CHARLES President and CEO Buy 5,325 $1.56 $8,307 No
2020-08-20 THEUER CHARLES President and CEO Buy 30,000 $1.58 $47,400 No
2020-08-18 THEUER CHARLES President and CEO Buy 44,843 $1.63 $73,021 No
2020-08-13 THEUER CHARLES President and CEO Buy 20,000 $1.73 $34,500 No
2020-06-24 THEUER CHARLES President and CEO Buy 9,895 $1.90 $18,800 No
2020-06-15 PELLETIER SAUNDRA L Director Buy 5,500 $2.04 $11,209 Yes
2020-05-22 THEUER CHARLES President and CEO Buy 10,592 $1.90 $20,119 No
2020-03-13 THEUER CHARLES President and CEO Buy 4,100 $1.13 $4,624 No
2020-03-12 THEUER CHARLES President and CEO Buy 20,000 $1.43 $28,639 No
2020-03-10 THEUER CHARLES President and CEO Buy 10,000 $1.87 $18,691 No
2020-01-23 WIGGINS MARK C Chief Business Officer Buy 5,000 $4.02 $20,102 No
2019-12-09 Puissance Cross-Border Opportunities V LLC 10%-Owner Sell 384,130 $2.93 $1,127,379 No
2019-08-09 THEUER CHARLES President and CEO Buy 50,000 $0.45 $22,500 No
2018-12-21 THEUER CHARLES President and CEO Buy 49,000 $0.66 $32,222 No
2018-03-27 Viswanathan Ravi 10%-Owner Buy 707,964 $2.70 $1,911,503 Yes

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.

Insider Smart

MGM Resorts International (MGM) - If we were to pick one of the easy trade from the crash, it has to be MGM, checkout the impressive insider buying after crash. Do you really need more confidence to pull the trigger? That's the mental edge you need to work against fear.